Market Research Industry Reports

Supernus Pharmaceuticals Inc (SUPN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Summary

Supernus Pharmaceuticals Inc (Supernus) is a specialty pharmaceutical company which develops and commercializes products for the treatment of central nervous system (CNS) diseases. The companys neurology portfolio consists of Oxtellar XR (oxcarbazepine), an adjunct therapy for the treatment of partial seizures; and Trokendi XR (topiramate), an initial monotherapy against partial onset or primary generalized tonic-clonic seizures and an adjunct therapy for the treatment of primary generalized tonic-clonic seizures associated with Lennox-Gastaut syndrome. Its technology platforms include Microtrol (multiparticulate delivery platform), Solutrol (matrix delivery platform) and EnSoTrol (osmotic delivery system). The company operates through its subsidiary Supernus Europe Ltd. Supernus is headquartered in Rockville, Maryland, the US.

Supernus Pharmaceuticals Inc (SUPN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.




Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Private Equity 10
HealthCare Royalty Acquires Orenitram from Supernus Pharma for USD30 Million 10
Licensing Agreements 11
Supernus Pharma Enters into Licensing Agreement with Zydus Pharma 11
Aequus Pharma Enters into Licensing Agreement with Supernus Pharma 12
Equity Offering 13
Supernus Pharma Completes Public Offering Of Common Stock For US$48 Million 13
Supernus Pharma Completes IPO For USD52.3 Million 15
Debt Offering 17
Supernus Pharma Prices Private Placement of Notes Due 2023 for USD350 Million 17
Supernus Pharma Completes Private Placement Of Notes Due 2019 For US$90 Million 18
Supernus Pharmaceuticals Inc - Key Competitors 20
Supernus Pharmaceuticals Inc - Key Employees 21
Supernus Pharmaceuticals Inc - Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
Feb 27, 2018: Supernus Announces Record Full Year 2017 Financial Results, Exceeding Operating Earnings Guidance 23
Nov 06, 2017: Supernus Announces Third Quarter 2017 Financial Results 25
Aug 02, 2017: Supernus Announces Record Second Quarter 2017 Financial Results 27
May 09, 2017: Supernus Announces First Quarter 2017 Financial Results 29
Feb 28, 2017: Supernus Announces Record Fourth Quarter and Full Year 2016 Financial Results 31
Appendix 33
Methodology 33
About GlobalData 33
Contact Us 33
Disclaimer 33

List Of Tables

List of Tables
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Supernus Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
HealthCare Royalty Acquires Orenitram from Supernus Pharma for USD30 Million 10
Supernus Pharma Enters into Licensing Agreement with Zydus Pharma 11
Aequus Pharma Enters into Licensing Agreement with Supernus Pharma 12
Supernus Pharma Completes Public Offering Of Common Stock For US$48 Million 13
Supernus Pharma Completes IPO For USD52.3 Million 15
Supernus Pharma Prices Private Placement of Notes Due 2023 for USD350 Million 17
Supernus Pharma Completes Private Placement Of Notes Due 2019 For US$90 Million 18
Supernus Pharmaceuticals Inc, Key Competitors 20
Supernus Pharmaceuticals Inc, Key Employees 21
Supernus Pharmaceuticals Inc, Subsidiaries 22

List Of Figures

List of Figures
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Supernus Pharmaceuticals Inc (SUPN) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Supernus Pharmaceuticals Inc (Supernus) is a specialty pharmaceutical company which develops and commercializes products for the treatment of central nervous system (CNS) diseases. The companys neurology portfolio consists of Oxtellar

USD 250View Report

Supernus Pharmaceuticals Inc Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Supernus Pharmaceuticals Inc Company Profile is a detailed strategic and analytical report on Supernus Pharmaceuticals Inc. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200View Report

Urigen Pharmaceuticals Inc - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Urigen Pharmaceuticals Inc (Urigen) is a specialty pharmaceutical company that develops and commercializes therapeutic products for urological disorders. The company focuses on developing innovative products for amelioration of urethritis, painful

USD 250View Report

Regeneron Pharmaceuticals Inc (REGN) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Regeneron Pharmaceuticals Inc (Regeneron) is a biopharmaceutical company, which discovers, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. The companys six US FDA-approved medicines and product

USD 250View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 250
  • Site Licence    USD 500
  • Enterprise Wide Licence    USD 750
$ 250

Reports Details

Published Date : Apr 2018
No. of Pages :33
Country :United States of America
Category :Pharmaceuticals and Healthcare
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube